Merck topped third-quarter estimates on Thursday and raised its adjusted profit outlook. The company said strong sales of its immunotherapy Keytruda, including the newer injectable form, drove the results.
Merck now expects adjusted earnings of $2.77 to $2.82 per share, up from a previous range of $2.66 to $2.76. The new guidance includes a one-time charge of $400 million, or 12 cents per share, tied to a licensing agreement with the Chinese cancer drugmaker SciBrunch.
Merck narrowed the low end of its 2026 revenue guidance to $66.8 billion to $67.3 billion, from $66.3 billion to $67.3 billion.
Keytruda sales reached $8.60 billion for the quarter, above the $7.73 billion analysts expected, according to StreetAccount. Sales of Keytruda Qlex, the under-the-skin injectable form, totaled $830 million, compared with analysts' expectations of $649 million. That was the highest quarterly figure for Qlex since its 2025 launch.
Merck reported net income of $5.07 billion, or $2.04 per share, versus $5.79 billion, or $2.32 per share, a year earlier. Excluding acquisition and restructuring costs, it earned $2.49 per share. Revenue was $18.09 billion, up 5% from a year earlier.
Other products also beat expectations. Winrevair, which treats a rare, deadly lung condition, brought in $694 million, up 93% from a year earlier and above the $645 million analysts expected. Gardasil, the HPV vaccine, generated about $2 billion on higher U.S. demand, above the $1.76 billion estimate. Merck's animal health business posted $1.68 billion, slightly below estimates.
Merck is pursuing a series of deals to offset generic competition for Keytruda after key patents begin expiring in 2028. The company has said it aims to move patients from the intravenous version of Keytruda to Qlex.